论文部分内容阅读
目的 1 3 1 I标记人源抗 HBs Ag Fab经腹腔注射治疗荷人肝癌裸鼠移植瘤 ,与 1 3 1 I- S1 0 2 比较 ,评价其作为肝癌放射免疫治疗 (RIT)的可能性。方法 荷瘤裸鼠分为 4组分别经腹腔注射不同放射剂量的 1 3 1 I-抗 HBs Ag Fab、1 3 1 I- S1 0 2 、1 3 1 I-无关 Fab及 PBS。按一定时间间隔作组织分布和血液清除速率测定 ,继续观察 4周 ,以外周血白细胞和血小板数量变化行毒性分析 ,计算各组肿瘤生长抑制率。结果 1 3 1 I-抗HBs Ag Fab被肿瘤区的摄取和在血液中清除速率均明显快于 1 3 1 I- S1 0 2 ,同等剂量下 ,前者抗肿瘤疗效略低 ,但血液毒性明显减轻。结论 人源抗 HBs Ag Fab具有良好的免疫结合活性 ,核素标记后用于 RIT,能够被肿瘤快速摄取并在体内正常组织中快速清除 ,毒性减低 ,具有良好的抗肿瘤疗效 ,是原发性肝癌 RIT的理想载体
Objective 1 3 1 I labeled human anti-HBs Ag Fab was injected intraperitoneally into human hepatoma xenografts in nude mice and compared with 131 I-S1 0 2 to evaluate its potential as a radioimmunotherapy (RIT) for liver cancer. Methods The tumor-bearing nude mice were divided into 4 groups by intraperitoneal injection of 131 I-anti-HBs Ag Fab, 131 I-S1 0 2, 1 3 1 I-unrelated Fab and PBS with different dosages. Tissue distribution and blood clearance rate were determined at certain time intervals, and the observation was continued for 4 weeks. Toxicity analysis of peripheral blood leukocytes and platelet count was performed to calculate the tumor growth inhibition rate of each group. Results 1 3 1 The anti-tumor efficacy of I-anti-HBs Ag Fab uptake in tumor area and clearance rate in blood was significantly faster than that of 131I-S1 0 2, and the anti-tumor efficacy was slightly lower at the same dose, but the blood toxicity was significantly reduced . Conclusion The human anti-HBs Ag Fab has good immunological binding activity. The radionuclide labeled for RIT can be quickly taken up by the tumor and rapidly cleared in the normal tissues of the body. The anti-HBs Ag Fab has good anti-tumor efficacy and is primary Liver cancer RIT ideal carrier